ADPRS-Related Stress-Induced Neurodegeneration (CONDSIAS): Comprehensive Research Report

1. Disease Information

Overview

ADPRS-Related Stress-Induced Neurodegeneration — formally designated CONDSIAS (Childhood-Onset Neurodegeneration, Stress-Induced, with variable Ataxia and Seizures) — is an ultra-rare, autosomal recessive neurodegenerative disorder caused by biallelic loss-of-function variants in ADPRS (formerly ADPRHL2), which encodes the enzyme ADP-ribosylhydrolase 3 (ARH3). Affected children are typically born after normal early development and then experience progressive, often stepwise neurological deterioration — ataxia, seizures, developmental regression — that is classically triggered or exacerbated by physiologic "stress," most commonly febrile infectious illness, but also surgery, vaccination, or emotional stress PMC6218634.

The disease was first delineated in 2018 by two independent groups publishing back-to-back: Danhauser et al. (9 individuals, 7 families) and Ghosh et al. (further families), both in the American Journal of Human Genetics PMC6218634. As of late 2024, approximately 50 cases from ~29 families and 23 distinct variants have been reported worldwide, making this one of the rarest known Mendelian neurodegenerative disorders ScienceDirect 2024.

Key Identifiers

Synonyms

• CONDSIAS
• Stress-induced childhood-onset neurodegeneration with variable ataxia and seizures
• ADPRHL2-related neurodegeneration / ADPRHL2 deficiency
• ARH3 deficiency
• "Degenerative pediatric stress-induced epileptic ataxia syndrome" (original 2018 title) ResearchGate erratum
• Gene synonyms: ADPRHL2 (older/legacy symbol), ARH3

Data Source Type

Nearly all clinical knowledge derives from aggregated case reports and small case series (individual patients and families identified via whole-exome/genome sequencing), not large-scale EHR or registry data, given the extreme rarity of the condition (<50 cases published cumulatively).

2. Etiology

Disease Causal Factors

CONDSIAS is caused exclusively by biallelic (homozygous or compound heterozygous) pathogenic variants in ADPRS that abolish or severely reduce ARH3 enzymatic activity or protein stability. There is no known non-genetic cause; the disorder is purely Mendelian, but its clinical expression is stress-gated — an environmental trigger (infection, fever) is required to precipitate or worsen episodes on the background of the genetic lesion PMC6218634.

Genetic Risk Factors

• Causal gene: ADPRS (HGNC:21304), biallelic loss-of-function or severely hypomorphic missense variants.
• Reported pathogenic variant types include: missense (e.g., c.1004T>G p.Val335Gly — the most recurrent allele, found in 6 of the original 8 families; c.545A>G p.His182Arg; c.484C>T p.Leu162Pro), nonsense (c.1038C>G p.Tyr346Ter; c.580C>T p.Gln194Ter), frameshift (c.292delG p.Val98Trpfs23), splice-site (c.309-1G>T; c.803-1G>A), and in-frame indel* (c.744_746del p.Lys248_Ile249delinsAsn) variants PMC6218634, PMC9160522, PMC11667697.
• Allele frequency: The most common recurrent variant (c.1004T>G, p.Val335Gly) was observed 27 times heterozygously among 277,240 gnomAD alleles, with no homozygotes reported in population databases — consistent with the extreme rarity and severity of biallelic loss PMC6218634. This implies a carrier frequency in the general population on the order of ~1 in 10,000, though this is not ancestry-stratified in available sources.
• Consanguinity is reported in several families with homozygous variants (e.g., c.1004T>G recurring in Turkish/Middle Eastern families), consistent with a founder or regionally enriched allele.

Modifier / Susceptibility Considerations

No modifier genes have yet been identified; disease severity instead correlates loosely with variant type (truncating/null alleles trend toward more severe, earlier, and fatal presentations vs. hypomorphic missense alleles, which may present later or with milder/adult-onset phenotypes — see PAMP syndrome below).

Environmental Risk Factors (Triggers)

The hallmark etiological feature is stress-triggered exacerbation: - Febrile/infectious illness (most common trigger — respiratory infections, diarrheal illness) - Physical stress (surgery, vaccination) - Emotional/psychological stress - The proposed mechanism is that cellular oxidative/genotoxic stress during illness increases poly(ADP-ribose) (PAR) generation by PARP1, which cannot be cleared in ARH3-deficient cells, precipitating a cell-death cascade (see Mechanism, Section 6) insight.jci.org.

Protective Factors

None have been established in humans. In model systems, pharmacological PARP1 inhibition (see Treatment) acts as a protective/rescue intervention against the downstream consequences of ARH3 loss, suggesting that anything reducing PARP1 activation during stress episodes may be protective — this remains experimental.

Gene-Environment Interaction

CONDSIAS is a paradigmatic gene-environment interaction disease: the genetic lesion (loss of ARH3) is necessary but the environmental trigger (oxidative/genotoxic stress from infection) is required to unmask cytotoxic PAR accumulation and precipitate clinical episodes — patients can be relatively stable between stress episodes, with stepwise deterioration occurring specifically during/after triggers PMC6218634.

3. Phenotypes

Core Neurological Phenotypes (from the founding cohorts, n=12 in Danhauser et al.; expanded across ~50 total cases)

Extended/atypical phenotypes reported in recent expansion papers (2023–2025): - Parkinsonism (truncal dystonia, bradykinesia) emerging in the second decade PubMed 40493129 - Ichthyosis and cataracts — novel extra-neurological associations PubMed 40493129 - Torticollis attacks as a presenting paroxysmal feature PMC9175411 - Dystonia and myelopathy - Cardiac involvement — cardiac arrest in roughly one-third of homozygous-mutant patients, described as possibly neurogenic in origin, implicating ARH3 in myocardial function maintenance (echoing the cardiac phenotype in Arh3 knockout mice) bioRxiv

Phenotype Characteristics

• Age of onset: Highly variable — from 14 months to 15 years across the combined literature, with most cases in early-mid childhood (median around 2–6 years); rarer adult-onset presentations (PAMP syndrome, see below) occur around age 20.
• Severity: Variable — ranges from milder ataxia-predominant courses to fulminant fatal presentations with seizures/respiratory failure within months of onset.
• Progression: Classically episodic/stepwise — periods of relative stability punctuated by acute stress-triggered deterioration, though some patients show more continuous progressive decline.
• Outcome heterogeneity: In the founding cohort, 3/12 died in childhood, 5/12 progressed into their teens; later reports document deaths from seizures (within months of onset in the most severe cases) and from respiratory/cardiac arrest during stress episodes.

Quality of Life Impact

Progressive loss of ambulation, dysarthria, seizures, and (in severe cases) ventilator dependence create substantial functional impairment; no formal EQ-5D/SF-36 data exist given the rarity of the disease, but case reports uniformly describe major impact on mobility, communication, and independence, often culminating in early mortality in the more severe genotypes.

4. Genetic/Molecular Information

Causal Gene

• ADPRS (HGNC:21304; MIM 610624), formerly ADPRHL2, located at chromosome 1 (1p34 region per OMIM), encodes ADP-ribosylhydrolase 3 (ARH3).

Pathogenic Variant Spectrum (compiled across case reports)

• Variant classification: Reported variants are classified Pathogenic/Likely Pathogenic per ACMG/AMP criteria (PVS1, PM2_Supporting, PS3, PM3 combinations cited in case reports) PMC9160522.
• Zygosity: Both homozygous (in consanguineous families or with founder alleles) and compound heterozygous genotypes are reported.
• Somatic vs. germline: All reported variants are germline.
• Functional consequence: Loss-of-function via (a) nonsense-mediated decay/truncation, (b) catalytic inactivation of the di-Mg²⁺ active site, or (c) protein destabilization and mislocalization (loss of nuclear import) as demonstrated for p.His182Arg, which has a protein half-life of ~2.4 hours vs. >8 hours for wild-type, and mislocalizes to cytoplasm only PMC11667697.

Modifier Genes / Epigenetics

No modifier genes or disease-specific epigenetic (DNA methylation/histone) studies have been reported. However, mechanistically, ARH3 loss causes abnormal persistence of mono-ADP-ribose ("PAR scars") on core histones after DNA strand-break repair — an epigenetic-adjacent chromatin mark — described in Fontana et al., Nature Communications 2020 Nature Comms 2020.

Chromosomal Abnormalities

None reported — CONDSIAS is caused by point mutations/small indels, not large structural rearrangements.

5. Environmental Information

• Environmental triggers are central to disease expression rather than causal on their own: febrile/infectious illness (most common), physical stress, and vaccination have all been documented as precipitants of acute deterioration episodes.
• Infectious agents: No specific pathogen is causally linked; a broad range of childhood infections (respiratory, gastrointestinal/diarrheal illness) have been documented as triggers in case reports, acting as generic inducers of physiologic/oxidative stress rather than direct pathogens of the nervous system.
• Lifestyle factors: Not applicable/described — this is a pediatric-onset monogenic disorder without known lifestyle risk modifiers.

6. Mechanism / Pathophysiology

Molecular Function of ARH3

ARH3 (ADP-ribosylhydrolase 3) is a di-Mg²⁺-dependent, all-α-helical fold hydrolase (structurally distinct from macrodomain hydrolases like PARG, MacroD2, TARG1) that: 1. Degrades protein-linked poly(ADP-ribose) (PAR) synthesized by PARP1/PARP2 during the DNA damage response and oxidative stress UniProt Q9NX46, PNAS. 2. Is the major serine-specific mono-ADP-ribosylhydrolase in cells, reversing serine-MARylation Nature Comms 2017. 3. Is uniquely important in mitochondria, where it is described as "the only known poly(ADP-ribose)-hydrolyzing enzyme," giving it a non-redundant role in mitochondrial ADP-ribose clearance PMC6218634. 4. Localizes to nucleus, cytoplasm, and mitochondria.

Causal Chain (Trigger → Clinical Manifestation)

1. Trigger: Physiologic stress (infection, fever) → oxidative stress and DNA single-strand breaks in neurons and other cells.
2. PARP1/PARP2 activation → massive synthesis of poly(ADP-ribose) (PAR) on nuclear proteins (histones) and elsewhere, as part of normal DNA damage response.
3. Failure of PAR clearance: In ARH3-deficient cells, PAR (and mono-ADP-ribose) cannot be degraded — "a ring-shaped signal remained in ADPRHL2-mutant fibroblasts" for hours after H2O2 exposure that normalized within 2 hours in controls PMC6218634.
4. PAR translocation and AIF release: Excess PAR translocates from nucleus to cytoplasm and to mitochondria, triggering release of a cleaved, pro-apoptotic form of apoptosis-inducing factor (AIF) from mitochondria insight.jci.org.
5. Parthanatos: AIF translocates to the nucleus, activating endonucleases and causing large-scale DNA fragmentation and chromatin condensation — this PARP1-dependent, AIF-mediated cell death pathway is termed parthanatos insight.jci.org, PMC review of parthanatos.
6. Cell death in vulnerable populations: Neurons (cerebellar Purkinje cells, peripheral axons) and cardiomyocytes appear particularly vulnerable, producing progressive cerebellar atrophy, axonal neuropathy, and in some cases cardiac dysfunction/arrest.
7. Chromatin "scarring": Even sublethal episodes leave persistent mono-ADP-ribose marks on core histones as a molecular memory of prior DNA strand-break repair, potentially compounding cumulative dysfunction with repeated stress episodes Nature Comms 2020.

Cellular Processes Involved

• DNA damage response / DNA strand-break repair
• Poly- and mono-ADP-ribosylation (PARylation/MARylation) signaling
• Regulated (parthanatic) cell death
• Mitochondrial dysfunction under low-glucose/high-oxidative-phosphorylation conditions — patient fibroblasts show significantly reduced viability specifically when forced toward mitochondrial respiration (galactose/low-glucose media with H2O2 challenge), but not under high-glucose (glycolytic) conditions, implicating mitochondrial energy stress as a key vulnerability PMC6218634.

Suggested GO Terms

• GO:0006471 protein ADP-ribosylation
• GO:0140290 peptidyl-serine ADP-deribosylation (or closest ARH3-specific catalytic activity term)
• GO:0006281 DNA repair
• GO:0006302 double-strand break repair (contextual)
• GO:0097345 mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (AIF release)
• GO:0006915 apoptotic process (parthanatos as regulated necrosis, GO:0097468 programmed necrotic cell death may also apply)

Suggested CL Terms

• CL:0000121 Purkinje cell (cerebellar atrophy)
• CL:0000540 neuron (generic, for axonal neuropathy)
• CL:0002305 cardiac myocyte (cardiac phenotype)
• CL:0002573 Schwann cell (peripheral neuropathy, if demyelinating component)

Functional/Rescue Evidence

• Transduction of ARH3-deficient fibroblasts with wild-type ADPRHL2 cDNA restored viability under stress conditions.
• The PARP1 inhibitor DPQ rescued cell viability in mutant fibroblasts, directly supporting PAR accumulation as the proximate pathomechanism PMC6218634.
• Arh3 knockout mouse cardiomyocytes and neurons show increased PAR accumulation and heightened vulnerability to ischemic/oxidative injury, rescued by PARP1 inhibitors veliparib and rucaparib (see Section 15) insight.jci.org, bioRxiv rucaparib.

7. Anatomical Structures Affected

Organ Level

• Primary: Central nervous system — cerebellum, spinal cord, cerebral cortex (secondary/late), peripheral nerves.
• Secondary: Cardiovascular system (cardiac dysfunction/arrest in ~1/3 of severe homozygotes); respiratory system (neurogenic/muscular respiratory insufficiency); skin (ichthyosis in atypical cases); eye (cataracts, ophthalmoplegia); ear (sensorineural hearing loss).
• Body systems involved: Nervous, cardiovascular, respiratory, integumentary (rare), ophthalmologic, auditory.

Tissue and Cell Level

• Cerebellar cortex/Purkinje cell layer (atrophy)
• Spinal cord (atrophy, myelopathy)
• Peripheral nerve axons (axonal neuropathy)
• Cardiac myocytes (per mouse model and human cardiac-arrest phenotype)
• Skeletal muscle (secondary, from denervation/weakness)

Subcellular Level

• Nucleus: site of PARP1-mediated PARylation and (in wild-type) ARH3-mediated PAR clearance; chromatin/histone ADP-ribose "scarring" (GO Cellular Component: nucleus, chromatin)
• Mitochondria: unique non-redundant site of ARH3 PAR-hydrolysis activity; site of AIF release
• Cytoplasm: site of PAR translocation and downstream signaling

Localization / Lateralization

Neurodegeneration is typically bilateral/symmetric (cerebellar atrophy, bilateral sensorineural hearing loss, bilateral peripheral neuropathy) — consistent with a systemic metabolic/genotoxic-stress mechanism rather than a focal lesion.

8. Temporal Development

• Onset: Pediatric, typically after a period of normal early development; reported range 14 months to 15 years (most commonly early-to-mid childhood, ~2–6 years). Rare adult-onset variant phenotype (PAMP syndrome, onset ~age 20) also described.
• Onset pattern: Acute/subacute — often abrupt deterioration during or shortly after a febrile/infectious illness in a previously well child.
• Progression: Episodic/stepwise deterioration punctuated by stress triggers, though some patients show more continuously progressive decline; disease course is highly variable even for the same genotype (documented phenotypic variability between siblings/patients sharing the identical mutation) PMC9175411.
• Disease duration: Ranges from a fulminant course (death within ~4 months of symptom onset in the most severe reported case) to a chronic, multi-decade course with survival into the second/third decade and evolving phenotype (e.g., later parkinsonism).
• Critical periods: Each stress/infectious episode represents a "critical period" of vulnerability during which irreversible neurological injury can accrue — this has direct implications for anticipatory/prophylactic management during intercurrent illness.
• Remission: No spontaneous disease-modifying remission is described; some acute symptoms (e.g., transient ataxia/psychosis in PAMP syndrome) can partially resolve between episodes, but cumulative injury (atrophy) is typically permanent/progressive.

9. Inheritance and Population

Epidemiology

• Prevalence/Incidence: Not formally established — CONDSIAS is documented almost exclusively through individual case reports; approximately 50 cases from ~29 families reported cumulatively worldwide since 2018 ScienceDirect 2024. No population-based prevalence estimate exists; this qualifies as an ultra-rare disease.

Inheritance Pattern

• Autosomal recessive. Both homozygous and compound heterozygous genotypes reported.
• Penetrance: Appears high among biallelic carriers of null/severely hypomorphic alleles, though clinical expressivity is highly variable — even siblings with the identical genotype can show markedly different severity/course PMC9175411, Karger Case Reports Neurol.
• Founder effect: The recurrent p.Val335Gly (c.1004T>G) allele, seen in 6 of the original 8 families, suggests a founder mutation in certain populations (reported disproportionately in Turkish/Middle Eastern-ancestry families in the literature).
• Consanguinity: A recognized risk factor given the homozygous presentations in multiple reported families.
• Carrier frequency: Approximately 27/277,240 gnomAD alleles heterozygous for the most common variant alone (~1/10,000), with additional rarer pathogenic alleles contributing to overall carrier burden; population-specific carrier frequency data are not systematically reported.

Population Demographics

• Reported cases span diverse ancestries, including European, Turkish, Middle Eastern, and Somali/African families PMC11667697.
• Sex ratio: No clear sex predilection reported (autosomal recessive; both sexes affected in reported cohorts).
• No specific geographic endemicity beyond scattered founder-allele clusters.

10. Diagnostics

Clinical/Laboratory Tests

• No specific diagnostic biomarker or lab test exists; laboratory findings in reported cases are nonspecific (e.g., elevated lactate, abnormal CSF findings, elevated cardiac enzymes during acute episodes) PMC9160522.
• EEG: Multifocal spike/epileptiform activity during seizure episodes.
• Brain/spine MRI: Progressive cerebellar atrophy (widened cerebellar sulci) is the most consistent imaging finding; spinal cord atrophy also documented; secondary cortical/basal ganglia/corpus callosum changes in advanced/hypoxic-injury cases.
• Nerve conduction studies/EMG: Confirm axonal peripheral neuropathy in affected individuals.
• Cardiac evaluation: Warranted given reported sudden cardiac arrest risk; echocardiography may show reduced ejection fraction analogous to the mouse model phenotype.

Genetic Testing

• Diagnosis is established by molecular genetic testing identifying biallelic pathogenic ADPRS variants — typically via trio whole-exome sequencing (WES) given the nonspecific, heterogeneous clinical presentation and extreme rarity PMC7397971.
• WES/WGS are the primary diagnostic modalities in the literature; no dedicated commercial gene panel is described, though ADPRS would be expected to be included on comprehensive pediatric neurodegeneration/ataxia gene panels.
• Functional/RNA studies (e.g., RNA-seq to confirm splice variant consequences, immunoblotting for protein loss, cellular PAR-accumulation assays) have been used in research settings to confirm variant pathogenicity but are not standard clinical tests.
• Single-gene ADPRS Sanger sequencing is appropriate for confirming a suspected/known familial variant or for carrier testing in relatives of an affected proband.

Clinical Criteria / Differential Diagnosis

No standardized formal diagnostic criteria exist (disease too rare for consensus criteria). Differential diagnosis includes other pediatric-onset progressive ataxia/neurodegeneration syndromes, particularly those with episodic/stress-triggered decompensation — e.g., mitochondrial disorders (e.g., Leigh syndrome, POLG-related disease), other DNA-repair disorders (ataxia-telangiectasia, ataxia with oculomotor apraxia), and metabolic decompensation disorders (organic acidemias, urea cycle disorders) — distinguished definitively by ADPRS molecular testing.

Screening

No newborn screening or population carrier screening program currently exists for ADPRS/CONDSIAS given its rarity; carrier screening would be relevant in known consanguineous families or those from populations with an identified founder allele, following standard reproductive genetic counseling pathways.

11. Outcome/Prognosis

• Mortality: Substantial — in the founding cohort, 3/12 patients died in childhood; subsequent case reports document deaths from intractable seizures (as early as 4 months after symptom onset in the most severe reported case) and from cardiac arrest/respiratory failure during stress episodes. Approximately one-third of homozygous ARH3-deficient patients reportedly die of cardiac arrest, suggested to be neurogenic bioRxiv.
• Survival heterogeneity: Some patients survive into their teens/second decade with progressive but survivable disability; a subset requires long-term ventilatory support (tracheostomy-dependent) PMC11667697.
• Morbidity: Progressive loss of ambulation, dysarthria, cognitive decline (variable), seizures, and in advanced cases ventilator dependence.
• Prognostic factors: Variant type (truncating/null vs. missense/hypomorphic) appears to influence severity, though genotype-phenotype correlation is imperfect (documented intra-familial variability with identical genotypes). Frequency/severity of stress-triggered episodes appears to drive cumulative disability.
• Recovery potential: Partial recovery between acute episodes is described in some milder cases (e.g., transient ataxia/psychosis resolving within months in PAMP syndrome), but cumulative structural injury (cerebellar/spinal atrophy) is generally irreversible.

12. Treatment

There is no approved disease-modifying therapy; management is currently supportive, with an emerging experimental rationale for PARP1-inhibitor repurposing.

Pharmacotherapy (Investigational/Off-label)

• PARP1 inhibitors — the leading mechanistic candidate therapeutic class, based on direct evidence that PARP1 inhibition rescues ARH3-deficient cells and mice from PAR-driven parthanatos:
• DPQ (PARP1 inhibitor) restored viability in patient-derived ARH3-deficient fibroblasts under oxidative stress PMC6218634.
• Veliparib dramatically reduced cerebral infarct size and PAR accumulation in ARH3-deficient mice subjected to brain ischemia insight.jci.org.
• Rucaparib improved cardiac dysfunction (hypertrophy, reduced ejection fraction, ischemia-reperfusion injury) in Arh3-knockout mice bioRxiv rucaparib.
• A human case report describes repurposing doxycycline (via a proposed anti-neuroinflammatory/mitochondrial-protective mechanism) in a patient with a novel ADPRHL2 missense mutation, though this is anecdotal ResearchGate.
• Suggested NCIT term: NCIT:C1647 (PARP Inhibitor) as a class; specific agents (rucaparib, veliparib) are CHEBI-mappable small molecules (e.g., rucaparib CHEBI:75033; veliparib).
• Immunomodulatory attempts (e.g., IVIG/gamma-globulin, corticosteroids) have been tried empirically in acute presentations without clear benefit PMC9160522.

Supportive and Rehabilitative Care

• Anti-seizure medications for symptomatic seizure control (agent selection not standardized; case reports describe use of various anticonvulsants).
• Physical, occupational, and speech therapy for ataxia/dysarthria/mobility support (NCIT:C15302 Physical Therapy).
• Respiratory support up to and including mechanical ventilation/tracheostomy for neurogenic respiratory insufficiency (NCIT:C15329 category — Surgical/Procedural, e.g., tracheostomy).
• Cardiac monitoring given the recognized risk of cardiac arrest; consideration of proactive cardiology involvement in known homozygotes.
• Aggressive, early treatment of febrile/infectious illness to blunt stress-triggered decompensation (a rational, though unproven, "prophylactic" strategy given the disease's stress-induced mechanism).

Experimental / Clinical Trials

No registered interventional clinical trials specific to CONDSIAS/ADPRS were identified on ClinicalTrials.gov in available sources; management data derive entirely from single-patient case reports and preclinical (mouse/cell) PARP-inhibitor studies. This represents a clear translational gap — repurposing of FDA-approved oncology PARP inhibitors (rucaparib, veliparib, olaparib) for compassionate/off-label use in CONDSIAS is a plausible near-term avenue given the strong preclinical mechanistic rationale, but has not been formally trialed in humans.

Genetic Counseling

Standard autosomal recessive counseling for parents of an affected child (25% recurrence risk per pregnancy); carrier testing of relatives and reproductive partners recommended in known-variant families; prenatal/preimplantation genetic testing is an option once the familial variant(s) are identified.

13. Prevention

• Primary prevention: Not applicable in the classic sense (monogenic recessive disease); genetic/reproductive counseling and carrier screening in at-risk (consanguineous or founder-allele) families is the primary preventive lever.
• Secondary prevention: Early diagnosis via genetic testing in children presenting with unexplained stress-triggered ataxia/seizures allows anticipatory guidance (e.g., aggressive fever/infection management, avoidance of unnecessary physiologic stressors) to potentially blunt acute deteriorations, though this is not evidence-based, only mechanistically plausible.
• Tertiary prevention: Prompt supportive management of intercurrent infections, seizure control, and cardiac/respiratory monitoring to minimize stress-triggered morbidity/mortality in known patients.
• Screening: No population or newborn screening program exists; targeted carrier screening is appropriate in families with a known pathogenic ADPRS allele or from populations bearing an identified founder variant.
• Prophylaxis: No established pharmacologic prophylaxis; PARP1 inhibition remains a theoretical/experimental prophylactic strategy pending clinical validation.

14. Other Species / Natural Disease

• No naturally occurring veterinary/companion-animal disease analog to CONDSIAS has been reported in available sources (unlike some Mendelian diseases with recognized veterinary counterparts).
• Orthologous gene: Mouse Adprs (Arh3), NCBI Taxon 10090 (Mus musculus), MGI:2140364 MGI — used extensively for engineered knockout modeling (see below), not natural disease.

15. Model Organisms

Mouse Models (the dominant model system for this disease)

• Arh3 (Adprs) knockout (KO) mice — the principal genetic model, generated and characterized across multiple studies:
• Neuro/oxidative-stress phenotype: Arh3-KO mouse neurons show sustained PAR elevation after oxidative stress and increased susceptibility to cell death via parthanatos; in vivo brain ischemia-reperfusion produces larger infarcts in KO mice, rescued by the PARP1 inhibitor veliparib insight.jci.org, JCI Insight.
• Cardiac phenotype: Arh3-KO mice develop cardiac hypertrophy, reduced ejection fraction, and enhanced susceptibility to myocardial ischemia-reperfusion injury; heterozygous (Arh3-HT) mice show an intermediate phenotype (reduced contractile reserve under dobutamine stress, increased infarct size) — a gene-dosage effect paralleling the recognized cardiac-arrest risk in human homozygotes. The PARP1 inhibitor rucaparib improved cardiac dysfunction and reduced ischemia-reperfusion injury in this model bioRxiv, rucaparib Arh3 mice.
• Molecular/chromatin phenotype: Patient-derived and Arh3-null cells accumulate persistent mono-ADP-ribose "scars" on core histones following DNA strand-break repair, a phenomenon studied mechanistically in Fontana et al. 2020 Nature Communications.

Cellular / In Vitro Models

• Patient-derived dermal fibroblasts are the primary human cellular model used across nearly all published studies — demonstrating impaired PAR clearance after H2O2 challenge, reduced viability under mitochondrial-respiration-forcing (low-glucose) conditions, and rescue by wild-type ADPRHL2 cDNA transduction or PARP1 inhibitor (DPQ) treatment PMC6218634.
• HEK293/transfection systems expressing wild-type vs. mutant ARH3-Flag constructs (e.g., H182R) have been used to dissect protein stability, half-life, and subcellular (nuclear vs. cytoplasmic) localization defects PMC11667697.

Model Characteristics — Recapitulation and Limitations

• The mouse KO model recapitulates the cardiac and cell-death/parthanatos biochemical phenotype convincingly and has directly informed the PARP-inhibitor therapeutic hypothesis, but a fully penetrant cerebellar ataxia/seizure/neurodegeneration phenotype paralleling the human CNS disease has not been prominently reported in these mouse studies as of the literature surveyed here — the mouse work has focused predominantly on ischemia-reperfusion (brain and cardiac) stress-challenge paradigms rather than spontaneous progressive ataxia, representing a translational gap between the human "spontaneous, stress-precipitated, cerebellum-predominant" phenotype and the induced-injury mouse paradigm.
• Patient fibroblasts robustly model the core PAR-clearance defect and stress-conditional viability phenotype but obviously cannot recapitulate CNS-specific vulnerability (e.g., Purkinje cell loss) directly.

Related Model: Arh2 (a paralog)

• A related paralog, ARH2, has also been studied in knockout mice (cardiac dysfunction, tumorigenesis, inflammation phenotypes), providing comparative insight into the ADP-ribosylhydrolase gene family's role in maintaining genome/organelle integrity, though ARH2 is not itself implicated in human CONDSIAS bioRxiv Arh2.

Summary of Key Evidence Gaps for Curation

1. No formally validated pathogenicity classification (ClinVar) data or systematic gnomAD carrier-frequency table could be independently retrieved beyond the single reported allele-count figure — worth verifying directly against gnomAD/ClinVar databases during curation.
2. Precise Orphanet and MONDO identifiers should be cross-checked against a live OMIM Clinical Synopsis or Monarch Initiative query (OMIM.org blocked WebFetch in this session; identifiers above were extracted via secondary aggregation and should be confirmed).
3. No dedicated CONDSIAS clinical trial exists; the PARP-inhibitor therapeutic rationale is preclinical/case-report level only and should be flagged as an emerging/experimental hypothesis rather than established treatment.
4. Genotype-phenotype correlation is documented as imperfect/variable (including intra-familial variability with identical genotype) and should be curated with appropriate hedging.

Sources

• OMIM #618170 — CONDSIAS
• OMIM #610624 — ADPRS gene
• Danhauser et al. 2018, AJHG — PMC6218634 (original description)
• Sharma et al., PMC9160522 — Compound heterozygous ADPRS case report
• PMC11667697 / ScienceDirect 2024–2025 — ARH3 H182R variant, respiratory failure / ScienceDirect
• Neurology Genetics 2023 — p.Leu162Pro variant
• Fontana et al. 2020, Nature Communications — ARH3 chromatin scars
• JCI Insight — PARP1 inhibition in ARH3-deficient mice/cells
• bioRxiv — Rucaparib improves cardiac dysfunction in Arh3-deficient mice
• PAMP syndrome — Neurological Sciences 2021 / PubMed 33528672
• PubMed 40493129 — Phenotypic diversity: Parkinsonism, ichthyosis, cataract
• PMC9175411 — Torticollis attacks, phenotypic variability
• PMC7397971 / BMC Neurology — Novel imaging/clinical phenotypes, frameshift variant
• UniProt Q9NX46 — ARH3 protein
• MGI:2140364 — Mouse Adprs gene
• GenCC — ADPRS gene-disease curation